These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24717632)

  • 1. N-acetylcysteine for COPD: the evidence remains inconclusive--authors' reply.
    Zheng JP; Zhong NS
    Lancet Respir Med; 2014 Apr; 2(4):e3-4. PubMed ID: 24717632
    [No Abstract]   [Full Text] [Related]  

  • 2. N-acetylcysteine for COPD: the evidence remains inconclusive.
    Turner RD; Bothamley GH
    Lancet Respir Med; 2014 Apr; 2(4):e3. PubMed ID: 24717631
    [No Abstract]   [Full Text] [Related]  

  • 3. N-acetylcysteine in COPD may be beneficial, but for whom?
    Cazzola M; Matera MG
    Lancet Respir Med; 2014 Mar; 2(3):166-7. PubMed ID: 24621673
    [No Abstract]   [Full Text] [Related]  

  • 4. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-acetylcysteine for chronic obstructive pulmonary disease?
    Lavietes MH
    Respiration; 1999; 66(6):491-2. PubMed ID: 10847827
    [No Abstract]   [Full Text] [Related]  

  • 6. [Acetylcysteine in the treatment of severe COPD].
    Dekhuijzen PN
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1222-6. PubMed ID: 16796172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics affect IPF treatment response to N-acetylcysteine.
    Lozano-Wilhelmi M
    Lancet Respir Med; 2015 Oct; 3(10):752. PubMed ID: 26388174
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
    Fowdar K; Chen H; He Z; Zhang J; Zhong X; Zhang J; Li M; Bai J
    Heart Lung; 2017; 46(2):120-128. PubMed ID: 28109565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acetylcysteine in chronic obstructive pulmonary disease. Secretolytic, antioxidant or placebo?].
    Randerath W; Galetke W
    Med Monatsschr Pharm; 2003 Nov; 26(11):375-8. PubMed ID: 14652922
    [No Abstract]   [Full Text] [Related]  

  • 10. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial.
    Johnson K; McEvoy CE; Naqvi S; Wendt C; Reilkoff RA; Kunisaki KM; Wetherbee EE; Nelson D; Tirouvanziam R; Niewoehner DE
    Int J Chron Obstruct Pulmon Dis; 2016; 11():799-807. PubMed ID: 27143871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression].
    Entzian P
    Pneumologie; 1998 Jul; 52(7):396-7. PubMed ID: 9738391
    [No Abstract]   [Full Text] [Related]  

  • 12. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease.
    Gerrits CM; Herings RM; Leufkens HG; Lammers JW
    Eur Respir J; 2003 May; 21(5):795-8. PubMed ID: 12765423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical N-acetylcysteine in ichthyosis: Experience in 18 patients.
    Kaplan L; Castelo-Soccio L
    Pediatr Dermatol; 2018 Jul; 35(4):528-530. PubMed ID: 29582451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetylcysteine somewhere between Scylla and Charybdis.
    Sochman J
    J Am Coll Cardiol; 2010 Sep; 56(13):1067; author reply 1067-8. PubMed ID: 20846610
    [No Abstract]   [Full Text] [Related]  

  • 15. IV versus oral N-acetylcysteine.
    Gupta AK; Su MK; Greller HA; Lee DC; Chan GM
    Ann Emerg Med; 2009 Dec; 54(6):857-8; author reply 858-9. PubMed ID: 19942075
    [No Abstract]   [Full Text] [Related]  

  • 16. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.
    Pela R; Calcagni AM; Subiaco S; Isidori P; Tubaldi A; Sanguinetti CM
    Respiration; 1999; 66(6):495-500. PubMed ID: 10575333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Acetylcysteine for the prevention of renal dysfunction in high-risk patients undergoing coronary bypass graft surgery: an unfulfilled promise?
    Filep JG
    Crit Care Med; 2007 May; 35(5):1431-3. PubMed ID: 17446744
    [No Abstract]   [Full Text] [Related]  

  • 18. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
    Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
    Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-acetylcysteine is unlikely to reduce hospitalisation for chronic obstructive pulmonary disease.
    Ernst P; Suissa S
    Eur Respir J; 2003 Nov; 22(5):865; author reply 865-6. PubMed ID: 14621098
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes.
    Zhang JQ; Zhang JQ; Liu H; Zhao ZH; Fang LZ; Liu L; Fu WP; Shu JK; Feng JG; Dai LM
    Int J Chron Obstruct Pulmon Dis; 2015; 10():917-23. PubMed ID: 25999707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.